# Bezlotoxumab Versus FMT for Multiple Recurrent CDI

> **NCT05077085** · PHASE4 · WITHDRAWN · sponsor: **Leiden University Medical Center**

## Conditions studied

- Clostridium Infections
- Clostridioides Difficile
- Enterocolitis, Pseudomembranous

## Interventions

- **DRUG:** Bezlotoxumab
- **PROCEDURE:** Fecal Microbiota Transplantation (FMT)
- **DRUG:** Vancomycin oral

## Key facts

- **NCT ID:** NCT05077085
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01
- **Primary completion:** 2024-07
- **Final completion:** 2024-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn
- **Last updated:** 2023-03-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077085, "Bezlotoxumab Versus FMT for Multiple Recurrent CDI". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05077085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*